Selinexor (KPT-33) is a drug that inhibits exportin 1 (XPO1 and CRM1), a nuclear transport protein that shuttles nuclear proteins through the nuclear pore and is responsible for the removal of proteins from the nucleus:
XPO1mediates the export of over 220 different cargo proteins, including some growth regulatory proteins and the vast majority of tumor suppressor proteins. Moreover, XPO1 appears to be the only nuclear exporter for key tumor suppressor proteins, including…p53, p73, FOXO, pRB, BRCA1 and PP2A…and the anti-inflammatory protein IkB, which inhibits NFkB (Figure 1).
Disruption of XPO1 functioning is an excellent strategy treatment of cancer – accumulation of tumor suppressor proteins in the nucleus should overwhelm the transcription of oncogenes, thereby suppressing expression of the cancer phenotype (Figure 2). XPO1 has been shown to be particularly important in cancers driven by KRAS mutations, for example, lung cancer:
KRAS has proven an unsuccessful pharmacological target. Kim et al. cataloged KRAS mutations in more than 100 non-small cell lung cancer (NSCLC)–derived cell lines and performed whole-genome mRNA expression analysis to identify potential synthetic-lethal genetic interactions with mutant KRAS. The authors then screened for short inhibitory RNAs (siRNAs) that reduced the viability of a KRAS mutant colorectal cancer cell line and found that siRNAs targeting genes encoding components of the nuclear export machinery, including XPO1, were the most effective. Targeting XPO1 in more than 50 KRAS mutant cell lines reduced their viability. The clinically available XPO1 inhibitor KPT-330 increased apoptosis in KRAS mutant cells. Tumor volumes in three mouse models of KRAS mutant–driven cancers were markedly reduced by KPT-330 compared with those in untreated mice. Inhibition of XPO1 in cultured cells led to nuclear accumulation of the nuclear factor κB (NF-κB) inhibitory protein IκBα. Knockdown of the gene encoding IκBα rendered the KRAS mutant cells resistant to the XPO1 inhibitor, suggesting that KRAS mutant cells rely on the continual nuclear export of IκBα to enable NF-κB–dependent signaling and cell survival.
A phase 1/2 trial of selinexor with docetaxel for non-small cell cancer (NSCLC) will be initiated in the future:
Selinexor will be administered once weekly starting one week before chemotherapy initiation (to permit pharmacodynamic assessment of selinexor alone and in combination with chemotherapy), in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Dose limiting toxicities (DLTs) will be assessed based on the first cycle (7-day lead-in plus 21-day cycle = 28 days) toxicity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.03. A standard 3 + 3 dose escalation paradigm will be used.
XPO1 in Acute Myelogenous Leukemia (AML)
In a phase 1 study of selinexor in 95 patients with relapsed or refractory AML, objective responses were seen in 11 of 81 evaluable patients (14%) and 25 patients (31%) had at least a 50% reduction in bone marrow blasts. Progression-free (PFS) and overall survival (OS) were significantly better among responders than non-responders: median PFS 5.1 months versus 1.3 months (p = 0.008) and median OS of 9.7 versus 2.7 months, respectively. Twelve patients had 89 serious adverse events – fifteen were judged to be at least possibly related to selinexor, including two fatalities: one from a decreased ejection fraction and for from respiratory failure and infection.
A second phase 1 study showed promising results when selinexor was combined with decitabine, a hypomethylating agent. [DNA methylation squelches expression of genes, including tumor suppressor genes.]
The SOPRA (Selinexor in Older Patients with Relapsed AML) was a randomized study comparing selinexor with investigator’s choice of therapy (control) in 176 patients with relapsed/refractory AML after a median of two prior regimens. The rate of complete response (CR) or CR with incomplete recovery of blood counts (CRi) was 13% in patients randomized to selinexor versus 3% for control, however, there was no significant difference in OS.
Karyopharm will be focused largely on the use of selinexor in multiple myeloma, diffuse large B-cell lymphoma, and liposarcoma.
Thank you, Kelly. We will do our best to continue that!